Abbott Laboratories (ABT)

On February 16, 2010, Abbott Laboratories announced that it had completed its acquisition of the pharmaceutical (including vaccine) and diagnostics businesses of the Solvay Group.  As part of the acquisition, pursuant to an amendment to the agreement included as Exhibit 2.1 hereto, Abbott has agreed that certain intercompany arrangements between the Solvay Group and the business acquired by Abbott will be directly transferred to Abbott.  The acquisition was completed on February 15, 2010.  A copy of the amendment is attached as Exhibit 2.2.  A copy of the press release announcing the completion of the acquisition transaction is attached as Exhibit 99.1.

The acquired business constitutes the global pharmaceutical business of the Solvay Group. The acquired business manufactures and distributes medical products in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology, and men’s and women’s health.

The acquired business was purchased by Abbott from Solvay, S.A., a Belgian company and the corporate parent of the Solvay Group. The purchase price for the acquisition was EUR 4.5 billion, or approximately $6.2 billion, paid by Abbott from cash on hand.   The transaction also includes payments of up to EUR 300 million if certain sales milestones are met between 2011 and 2013.

—Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this Form 8-K may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to Abbott’s Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2008.  Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

Item 2.01 - Completion of Acquisition or Disposition of Assets.

                The information set forth under Item 1.01 of this current report on Form 8-K is hereby incorporated by reference in this Item 2.01.

2